IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
`
`Attorney Docket No.: 15730.02039.U825/203 9E
`
`Art Unit
`Examiner
`
`Conf. N0.
`Cust. N0.
`
`1673
`:
`: Lau, Jonathan S.
`
`:
`:
`
`9155
`26263
`
`Applicant
`Serial No.
`
`: H elenek el‘ al.
`:
`14/683,415
`
`: April 10, 2015
`
`Filed
`
`Title
`
`: METHODS AND COMPOSITIONS FOR ADMINISTRATION OF
`IRON
`
`Mail Stop Amendment
`Commissioner for Patents
`PO. Box 1450
`
`Alexandria, VA 22313—1450
`
`SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN
`
`ACCORDANCE WITH 37 C.F.R. §§ 1.97-1.98
`
`Dear Sir:
`
`Because this Supplemental Information Disclosure Statement is filed before the
`
`receipt of a First Office Action on the Merits for the above-captioned application, a fee is not
`
`required. If it is determined that a fee for filing these papers is required, the Commissioner is
`
`authorized to charge Deposit Account No. 50—091 1.
`
`In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 to inform the
`
`Patent Office of all information known by Applicant or Applicant's representative that may
`
`be material to the examination of the subject application, Applicant‘s representative hereby
`provides this Supplemental Information Disclosure Statement that is prepared in accordance
`
`with 37 C.F.R. §§ 1 .97—1 .98. Forms PTO—1449 (5 pages) and copies ofthe cited non—US.
`
`patent documents are provided herewith in connection with the above-captioned application.
`
`The documents cited on the Forms PTO—1449 are in the English language. Hence, in
`
`accordance with the requirements of 37 C.F.R. § 1.98, no further explanation of the listed
`
`items is necessary.
`
`Although these documents and applications are made known to the Patent and
`
`Trademark Office in compliance With Applicant's duty of disclosure, such disclosure is not to
`
`be construed as an admission by Applicant or Applicant's representative that any of the
`
`documents, singly or in any combination thereof, is effective as prior art against the subject
`
`application. In accordance with 37 C.F.R. § 1.97(g) and (h), the filing of this Supplemental
`
`Information Disclosure Statement shall not be construed to mean that a search has been made
`
`or that no other material information as defined in 37 C.F.R. § 1.56(b) exists.
`
`CERTIFICATE OF TRANSMISSION VIA EFS-WEB
`
`EX. 3002
`
`Ex. 3002
`PGR2020-00009
`
`PGR2020-00009
`
`I hereby certify that this paper is being transmitted via the
`Electronic Filing System (EFS-WEB) to the United States Patent
`and Trademark
`fficc January 27, 2017.
`
`bat wot/w: [4
`
`Robert Chomik
`
`

`

`Applicant
`Serial No.
`Filed
`
`: Helenek et al.
`:
`14/683,415
`: April 10, 2015
`
`Attorney Docket N0.: 15730.02039.U825/2039E
`Supplemental Information Disclosure Statement
`
`Applicant respectfully requests that the Examiner review the Oregoing documents
`
`and they be made of record in the file history of the abo —captio ed application.
` Respectful
`
`
`
`Stephanie Seidman
`Reg. No. 33,779
`
`Attorney Docket No. 15730.02039.U825/2039E
`Address all correspondence to: 13565
`Stephanie Seidman
`Dentons US LLP
`
`4655 Executive Dr., Ste. 700
`
`San Diego, California 92121
`Telephone: (619) 595-8010
`Facsimile:
`(619) 595—8135
`email: stephanie.seid1nan@dent0ns . com
`
`

`

`Sheet L ofi
`
`Substitute Form PTO-1449
`(Modified)
`
`us. Department of Commerce Attorney Docket No.
`Patent and Trademark Office
`15730.02039.U825/203 9E
`
`Application No.
`14/683,415
`
`List of Patents and Publications for Applicant’s
`Information Disclosure Statement
`(37 CFR §1_98(b))
`
`Helenek er or].
`FilingPate
`April 10, 2015
`U. S. Patent Documents
`
`Group A” Unit
`1673
`
`Examiner
`Initial
`
`Desig.
`ID
`
`Document
`Number
`
`Publication
`Date
`
`Patentee
`
`Class
`
`Subclass
`
`Filing Date
`If A o o ro o riate
`
`01/08/2007
`Helenek et 31.
`07/13/10
`7754 702
`
`
`8,431,549
`
`04/03/13
`
`Helenek et a1.
`
`05/25/2010
`
`Examiner
`Initial
`
`Foreign Patent Documents or Published Foreign Patent Applications
`Desig.
`Document
`Publication
`Country or Patent
`Translation
`ID
`Number
`Date
`Office
`
`None
`
`Examiner
`Initial
`
`Other Documents (include Author, Title, Date, and Place of Publication)
`Desig.
`ID
`
`Document
`Letter/Written Disclosure of the initial Information Disclosure Statement for the above -referenced
`
`
`
`.
`a lieation, filed herewith on Janu
`Auerbaeh et a1., "Low-molecular weight1r0n dextran and iron sucrose have similar comparative
`safety profiles in chronic kidney disease," Kidney International 73:528-530 (2008).
`Danielson B .G., "Structure, chemistry, and pharmacokinetics of intravenous iron agents," J Am Soc
`Nephrol 15 Suppl 2:S93-S98 (2004).
`Decision of the Technical Board of Appeal, dated March 1, 2006, in connection with European
`Patent No. 0679508, 17 pages.
`
`Jahn et al., "A comparative study of the physiochemical properties of iron isomaltoside 1000
`(Monofer), a new intravenous iron preparation and its clinical implications," European J of
`' uharmaceutics 78:480-491 (2011).
`Johansson et al., "Intravenous iron isomaltoside 1000 (Monofer®) reduces postoperative anaemia in
`preoperatively non-anaemic patients undergoing elective or subacute coronary artery bypass graft,
`valve replacement or a combination thereof: a randomized double-blind placebo-controlled clinical
`trial (the PROTECT trial)," Vox Sang 109(3):257-266 (2015).
`Kulnigg et al., "A novel intravenous iron formulation for treatment of anemia in inflammatory
`bowel disease: the ferric carboxyrnaltose (FERINJECT) randomized controlled trial," Am J
`Gastroenterol 103(5): 1 182-1 192 (2008).
`MacDougall et a1., "Use of intravenous iron supplementation in chronic kidney disease" Iranian J
`Kidney Dis 7(1):9-22 (2013).
`MacDougall I.C., "Strategies for iron supplementation: Oral versus intravenous" Kidney
`International 55(69): 861-66 (1999).
`Reiniseh et al., "A randomized, open-label, non—inferiority study of intravenous iron isomaltoside
`1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED)," Am J
`Gastroenterol 108(12): 1877-88 (20 1 3).
`Reiniseh et al., "A 1-year trial of repeated high-dose intravenous iron isomaltoside 1000 to maintain
`stable hemoglobin levels in inflammatory bowel disease," Scand J Gastroenterol 50(10): 1226-1233
`(2015).
`Syner-Med, "Summary of Product Characteristics; Ferinject," (2009), 8 pages.
`
`Office Action, mailed Dec. 15, 2009, in connection with US. Patent Application Serial No.
`11/620,986, 21 pages.
`Response, dated Jan. 08, 2010, in connection with US. Patent Application Serial No. 11/620,986,
`13 pages.
`
`Examiner Signature
`
`Date Considered
`
`Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in
`EXAMINER:
`conformance and not considered. Include copy of this form with next communication to applicant.
`
`

`

`Sheet L ofi
`
`Substitute Form PTO-1449
`(Modified)
`
`us. Department of Commerce Attorney Docket No.
`Patent and Trademark Office
`15730.02039US25/203 9E
`
`Application No.
`14/683,415
`
`List of Patents and Publications for Applicant’s
`Information Disclosure Statement
`(37 CFR §1.98(b))
`
`Helenek er all
`Group A” Unit
`FilingPate
`1673
`April 10, 2015
`Notice of Allowance, mailed April 5, 2010, in connection with US. Patent Application Serial No.
`
`11/620,986, 12 pages.
`Petition for Inter Partes Review of US. Patent No. 7,754,702, mailed June 24, 20 15, in connection
`with US. Patent Application Serial No. 11/620,986, 65 pages.
`Patent Owner Preliminary Response, dated Oct. 12, 2015, in connection with US. Patent
`Application Serial No. 11/620,986 (US. Patent No. 7,754,702), 39 pages.
`Decision, entered Jan. 08, 2016, in connection with U. S. Patent Application Serial No. 11/620,986
`(US. Patcnt No. 7,754,702), 20 pagcs.
`Order Conduct of the Proceedings, mailed Mar. 11, 2016, in connection with U. S. Patent
`Application Serial No. 11/620,986 (US. Patent No. 7,754,702), 6 pages.
`Patent Owner Response, mailed Mar. 29, 2016, in connection with US. Patent Application Serial
`
`No. 11/620,986 (US. Patent No. 7,754,702), 47 pages.
`Patent Owner Exhibit List as of March 29, 2016, mailed Mar. 29, 2016, in connection with US.
`Patent Application Serial No. 11/620,986 (US. Patent No. 7,754,702), 7 pages.
`Motion to Amend, mailed Mar. 29, 2016, in connection with US. Patent Application Serial No.
`11/620,986 (US. Patent No. 7,754,702), 48 pages.
`Petitioner's Notice of Objections to Evidence, mailed Apr. 5, 2016, in connection with U. S. Patent
`Application Serial No. 11/620,986 (US. Patent No. 7,754,702), 5 pages.
`Corrected Patent Owner Exhibit List as of April 25, 2016, mailed Apr. 25, 2016, in connection with
`US. Patent Application Serial No. l l/620,986 (US. Patent No. 7,754,702),7 pages.
`Corrected Motion to Amend, mailed Apr. 25, 2016, in connection with US. Patent Application
`
`Serial No. 11/620,986 (US. Patent No. 7,754,702), 48 pages.
`Petitioner's Reply to Patent Owner Response, dated June, 20, 2016, in connection with US. Patent
`A lication Serial No. 11/620,986 (Us. Patent No. 7,754,702), 32 '
`Petitioner's Opposition to Patent Owner's Motion to Amend, dated June 20, 2016, in connection
`with US. Patent A lication Serial No. 11/620,986 (US. Patent No. 7,754,702), 31
`.
`Objections to Petitioner's Reply and Opposition Evidence, dated June 27, 2016, in connection with
`US. Patcnt A .lication Scrial No. 11/620,986 (US. Patent No. 7,754,702), 5 .a
`.
`Patcnt Owncr Reply to Opposition to Motion to Amend, datcd July 19, 2016, in connection with
`U. S. Patent A ulication Serial No. 11/620, 986 (U. S. Patent No. 7 7,54 ,702), 20
`Patent Owner Motion to Exclude, dated Aug. 09, 2016, in connection with U. S. Patent Application
`
`Serial No. 11/620,986 (US. Patent No. 7,754,702), 19 pages.
`Order Conduct of the Proceedings, dated Aug. 19, 2016, in connection with US. Patent Application
`Serial No. 11/620,986 (US. Patent No. 7,754,702), 3 u,aes.
`Order Trial Hearing, dated Aug. 22, 2016, in connection with US. Patent Application Serial Nos.
`11/620,986 (US. Patent No. 7,754,702), 5 pages.
`Petitioner's Opposition to Patent Owner's Motion to Exclude, dated Aug. 23, 2016, in connection
`with US. Patcnt Application Serial No. ll/620,986 (U.S. Patcnt No. 7,754,702), 19 pagcs.
`Patcnt Owncr Reply to Opposition to Motion to Excludc, datcd Aug. 30, 2016, in conncction with
`US. Patent Application Serial No. l l/620,986 (US. Patent No. 7,754,702), 9 pages.
`Record of Oral Hearing, dated Nov. 03, 2016, in connection with US. Patent Application Serial No.
`
`11/620,986 (US. Patent No. 7,754,702), 104 pages.
`Final Written Decision, dated Jan. 4, 2017, in connection with U. S. Patent Application Serial No.
`11/620,986 (US. Patent No. 7,754,702), 52
`.
`Restriction Requirement, dated March 23, 2012, in connection with US. Patent Application Serial
`No. 12/787,283, 7 pages.
`Response, dated April 19, 2012, to Restriction Requirement, mailed March 23, 2012, in connection
`with US. Patcnt Application Scrial No. l2/787,283, 4 pagcs.
`Officc Action, mailcd Junc 6, 2012, in conncction with US. Patcnt Application Serial No.
`12/787,283, 13 pages.
`Response, dated Dec. 6, 2012, to Office Action, mailed June 6, 2012, in connection with US. Patent
`Application Serial No. 12/787,283, 34 pages.
`Date Considered
`
`
`
`Examiner Signature
`
`Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in
`EXAMINER:
`conformance and not considered. Include copy of this form with next communication to applicant.
`
`

`

`Sheet i of 5
`
`Substitute Form PTO-1449
`(Modified)
`
`us. Department of Commerce Attorney Docket No.
`Patent and Trademark Office
`15730.02039.US25/203 9E
`
`Application No.
`14/683,415
`
`List of Patents and Publications for Applicant’s
`Information Disclosure Statement
`(37 CFR §1_98(b))
`
`Helenek er all
`Group A” Unit
`FilingPate
`1673
`April 10, 2015
`Applicant—Initiated Interview Summary, mailed Feb. 6, 2013, in connection with US. Patent
`
`Application Serial No. 12/787,283, 4 pages.
`Notice of Allowance, mailed Feb. 28, 2013, in connection with US. Patent Application Serial No.
`12/787,283, 14 pages.
`Petition for Inter Partes Review of US. Patent No. 8,431,549, dated June 24, 2015, in connection
`with US. Patent Application Serial No. 12/787,283, 67 pages.
`Patent Owner Preliminary Response, dated Oct. 12, 2015, in connection with US. Patent
`Application Serial No. 12/787,283 (US. Patent No. 8,431,549), 65 pages.
`Order Conduct of the Proceeding, entered Oct. 14, 2015, in connection with US. Patent Application
`Serial No. 12/787,283 (US. Patent No. 8,431,549), 4 pages.
`Notice of Response in lieu of Motion, dated Oct. 20, 2015, in connection with US. Patent
`
`Application Serial No. 12/787,283 (US. Patent No.,431,549), 4 pages.
`Petitioner's Objection to Patent Owner Response in Lieu of Motion, dated Oct. 30, 2015, in
`connection Willi US. Patent Application Serial No. 12/787,283 (US. Patent No. 8,43 1,549), 4
`pages.
`Inter Partes Review Decision, entered Jan. 08, 2016, in connection with US. Patent Application
`Serial No. l2/787,283 (US. Patent No. 8,431,549), 24 pages.
`Request for Rehearing, dated Jan. 22, 2016, in connection with US. Patent Application Serial No.
`12/787,283 (US. Patent No. 8,431,549), 8 pages.
`Patent Owner Objections to Evidence, dated Jan. 27, 2016, in connection with US. Patent
`
`Application Serial No. 12/787,283 (US. Patent No. 8,431,549), 4 pages.
`Revised Patent Owner Notice of Deposition of Dr. Linhardt, dated Feb. 19, 2016, in connection
`with US. Patent An nlication Serial No. 12/787,283 (US. Patent No. 8,431,549), 3 macs.
`Decision Denying Petitioner's Request for Rehearing, entered Feb. 26, 2016, in connection with
`US. Patent A lication Serial No. 12/787,283 (US. Patent No. 8,431,549), 5 a .
`Order re Conference Call on March 09, 2016, entered Mar. 11, 2016, in connection with US. Patent
`A .lication Serial No. 12/787,283 (US. Patent No. 8,431,549), 6
`.
`Patent Owner Exhibit List as of July 19, 2016 in connection with US. Patent Application Serial No.
`12/787,283 (US. Patent No. 8,431,549), 7 ua_es.
`Patent Owner Reply to Opposition to Motion to Amend, dated July 19, 2016, in connection with
`
`US. Patent Application Serial No. 12/787,283 (US. Patent No. 8,43 1,549), 20 pages.
`Order Trial Hearing, dated Aug. 22, 2016, in connection with US. Patent Application Serial No.
`12/787,283 (US. Patent No. 8,431,549), 5
`.
`Record of Oral Hearing, dated Nov. 03, 2016, in connection with US. Patent Application Serial No.
`12/787,283 (US. Patent No. 8,431,549), 104 pages.
`Inter Partes Review Final Written Decision, filed Dec. 28, 2016, in connection with US. Patent
`Application Serial No. 12/787,283 (US. Patent No. 8,431,549), 28 pages.
`Restriction Requirement, mailed Dec. 30, 2013, in connection with US. Patent Application Serial
`No. 13/847,254, 7 pages.
`Response, dated Feb. 28, 2014, to Restriction Requirement, mailed Dec. 30, 2013, in connection
`with US. Patent A ulication Serial No. 13/847,254, 4
`.
`Office Action, mailed Apr. 07, 2014, in connection with US. Patent Application Serial No.
`13/847,254, 17
`.
`Response, dated July 03, 2014, to Office Action, mailed Apr. 07, 2014, in connection with US.
`Patent Application Serial No. l3/847,254, 18 pages.
`Office Action, mailed Oct. 14, 2014, in connection with US. Patent Application Serial No.
`13/847,254, 14 pages.
`Office Action, mailed Feb. 7, 2014, in connection with US. Patent Application Serial No.
`14/100,717, 15 pages.
`Response, filed June 9, 2014, to Office Action, mailed Feb. 7, 2014, in connection with U. S. Patent
`Application Serial No. 14/ 100,717, 19 pages.
`
`
`
`Examiner Signature
`
`Date Considered
`
`Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in
`EXAMINER:
`conformance and not considered. Include copy of this form with next communication to applicant.
`
`

`

`Sheet i of 5
`
`Substitute Form PTO-1449
`(Modified)
`
`us. Department of Commerce Attorney Docket No.
`Patent and Trademark Office
`15730.02039.US25/203 9E
`
`Application No.
`14/683,415
`
`List of Patents and Publications for Applicant’s
`Information Disclosure Statement
`(37 CFR §1_98(b))
`
`Helenek er a].
`Group A” Unit
`FilingPate
`1673
`April 10, 2015
`Notice of Allowance, mailed Sept. 22, 2014, in connection with US. Patent Application Serial No.
`
`14/100,717, 14 pages.
`Petition for Inter Partcs Review of US. Patent No. 8,895,612, filed June 24, 2015, in connection
`with U.S. Patent Application Serial No. 14/100,717, 68 pages.
`Patent Owner Preliminary Response, dated Oct. l2, 20] 5, to Petition for Inter Partcs Review, filed
`June 24, 2015, in connection with US. Patent Application Serial No. l4/100,7l7 (U .S. Patent No.
`8,895,612), 70 pagcs.
`Decision Dcnying Institution of Intcr Partcs Rcvicw, cntcrcd Jan. 8, 2016, in conncction with US.
`Patent Application Serial No. 14/100,717 (US. Patent No. 8,895,612), 23 pages.
`Response, dated May 17, 2013, to Office Action issued in connection with Australian Patent
`
`Application No. 2007205167, 28 pages.
`Notice of Acceptance, mailed June 04, 2013, in connection with Australian Patent Application No.
`2007205167, 1 page.
`Examination Report, issued Apr. 13, 2O 15, in connection with Australian Patent Application No,
`2013206429, 4 pages.
`to Examination Report, issued Apr. 13, 2015, in connection with
`Response, dated Mar. 22, 2016,
`Australian Patcnt Application No. 2013206429, 36 pagcs.
`Notice of Acceptance, issued Apr. 14, 2016, in connection with Australian Patent Application No.
`2013206429, 3 pages.
`Examination Report, issued Jan. 1 l, 2017, in connection with Australian Patent Application No.
`
`2016205002, 5 pages.
`Response, dated July 4, 2013, to Examiner's Report, issued Jan. 4, 2013, in connection with
`Canadian Patent A lication No. 2,635,894, 26 '
`Examiner's Report, issued Oct. 17, 2013, in connection with Canadian Patent Application No.
`2,63 5,894, 4
`.
`Response, dated April 16, 2014, to Examiner's Report, issued Oct. 17, 2013,
`Canadian Patent A 0 ulication No. 2,635,894, 33
`.
`Examincr's chort, issucd Oct. 10, 2014, in conncction with Canadian Patcnt Application No.
`2,635,894, 7 ua_es.
`in connection with
`Response, dated April 8, 2015, to Examiner's Report, issued Oct. 10, 2014,
`
`Canadian Patent Application No. 2,635,894, 30 pages.
`Examiner's Report, issued Sept. 29, 2015, in connection with Canadian Patent Application No.
`2,63 5,894, 8
`.
`Response, dated March 23, 2016, to Examiner's Report, issued Sept. 29, 2015, in connection with
`Canadian Patent Application No. 2,635,894, 19 pages.
`Examiner's Report, issued May 16, 2016, in connection with Canadian Patent Application No.
`2,63 5,894, 8 pages.
`Rcsponsc, datcd Nov. 15, 2016, to Examincr's chort, issucd May 16, 2016, in conncction with
`Canadian Patent Application No. 2,635,894, 24 pages.
`Examination Report, issued May 10, 2011, in connection with European Patent Application No.
`077163095, 6
`.
`Response, dated Dec. 14, 2012, to Examination Report, dated June 4, 2012, in connection with
`Euro ean Patent A lication No. 077163095, 17 a .
`Response, dated Jan. 15, 2014, to Examination Report, dated July 5, 2013, in connection with
`European Patent Application No. 077163095, 19 pages.
`Third Party Observations, submitted Oct. 3 l, 2014, and Communication pursuant to Rule 114(2)
`EPC, dated Nov. 10, 2014, in connection with European Patent Application No. 077163095 [Third
`party observations, Communication and cited references], 22 pages.
`Summons to Attend Oral Proceedings, dated Feb. 9, 2015, issued in connection with European
`Patent A lication No. 077163095, 4
`.
`Response, dated Oct. 30, 2015, to Summons to Attend Oral Proceedings, dated Feb. 9, 2015, in
`connection with European Patent Application No. 077 16309.5, 98 pages.
`Date Considered
`
`
`
`in connection with
`
`Examiner Signature
`
`Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in
`EXAMINER:
`conformance and not considered. Include copy of this form with next communication to applicant.
`
`

`

`
`
`Sheet 5 of 5
`
`Substitute Form PTO-1449
`(Modified)
`
`us. Department of Commerce Attorney Docket No.
`Patent and Trademark Office
`15730.02039.US25/203 9E
`
`Application No.
`14/683,415
`
`List of Patents and Publications for Applicant’s
`Information Disclosure Statement
`(37 CFR §1_98(b))
`
`Helenek er a].
`Group A” Unit
`FilingPate
`1673
`April 10, 2015
`Third Party Observations, submitted Nov. 11, 2015, and Communication maintaining the date/time
`for oral proceedings, dated Nov. 12, 20 15, in connection with European Patent Application No.
`077163095, 4 pages.
`Response, dated Nov. 27, 2015, to Notice Concerning the Oral Proceedings, dated Nov. 19, 2015, in
`connection with European Patent Application No. 077 16309.5, 67 pages.
`Decision to Grant, dated June 23, 2016, issued in connection With European Patent Application No.
`077163095, 2 pagcs.
`Examination chort, issucd April 7, 20 14, in conncction with European Patcnt Application No.
`131669889, 4 pages.
`Response, dated Oct. 17, 2014, to Examination Report, issued April 7, 2014, in connection with
`
`European Patent Application No. 131669889, 13 pages.
`Third Party Observations, submitted Nov. 03, 2014, in connection with European Patent
`Application No. 131669889, 2 pages.
`Summons to Attend Oral Proceedings, dated Feb. 10, 2015, in connection with European Patent
`Application No. 131669889, 6 pages.
`Response, dated Oct. 30, 2015, to Summons to Attend Oral Proceedings, dated Feb. 10, 2015, in
`conncction with Europcan Patcnt Application No. 13 1669889, 91 pages.
`Third Party Observations, submitted Nov. 11, 2015, and Communication maintaining the date/time
`for oral proceedings, dated Nov. 12, 20 15, in connection with European Patent Application No.
`
`131669889, 4 pages.
`Response, dated Nov. 23, 2015, to Summons to Attend Oral Proceedings, dated Feb. 10, 2015, in
`connection with European Patent Application No. 13 1669889, 13 pages.
`Communication from the Patent Office, issued Nov. 30, 2015, in connection with European Patent
`A 0 lication No. 131669889, 1 nae.
`Response, dated Nov. 27, 20 15, in connection With European Patent Application No. 13 1669889,
`
`Extended European Search Report, dated Aug. 3, 2016, in connection with European Patent
`
`Application No. 161728266, 13 pages.
`Office Action, dated Aug. 30, 20 16, in connection with Korean Patent Application No. 10 -20 14-
`7024469 [En lish translation], 7 a .
`Invalidation Request, filed June 20, 2016, in connection with Chinese Patent Application No.
`200780002006 [English translation, document as filed in Chinese and Notice of acceptance of
`invalidation request as issued in Chinese], 174 pages.
`Response, filed Aug. 23, 2016, to Invalidation Request, filed June 20, 2016, in connection with
`Chinese Patent Application No. 2007 80002006 [English instructions, document as filed in Chinese
`and claims as filed in English], 118 pages.
`Notice of Oral Hearing, issued Aug. 31, 2016, in connection with Chinese Patent Application No.
`
`2007 80002006 [English translation], 5 pages.
`Post Hearing Observations, filed Dec. 8, 20 16, on Response, filed Aug. 23, 2016, to Invalidation
`Request, filed June 20, 2016,in connection with Chinese Patent Application No. 200780002006
`[English instructions for response, document as filed in Chinese and English translation of filed
`claims], 57 pages.
`
`
`
`Examiner Signature
`
`Date Considered
`
`Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in
`EXAMINER:
`conformance and not considered. Include copy of this form with next communication to applicant.
`
`